|
|
|
Wednesday, June 18, 2014
|
 |
|
|
 |
Download Brochure
|
|
|
Application note : Parallel screening of 214 mutations with LungCartaTM Panel for clinical research
Agena Bioscience (formerly known as Sequenom) Massarray&trade system
|
|
| LungCarta&trade Panel Introduction |
|
| List of genes & mutations included in the panel |
|
- Screen 214 mutations in 26 tumor suppressors and oncogenes in parallel.
- Detect and quantify mutations with frequencies/abundance as low as 5%.
|
| Compatible sample type |
- Fresh tumor samples
- Frozen tumor samples
|
- Formalin fixed, paraffin embedded tissues (FFPE)
- Cell lines
|
| Click to see Test performance data |
|
Results Reporting
After spectra are obtained on the MassARRAY Analyzer 4 System, the Typer software creates a set of oncomutation reports including a:
- Mutation List: List of mutations that are above the mutation frequency cutoff
- Uncertain Confidence Mutations: Table of uncertain confidence mutations with failed assays or partially failed assays that do not provide enough information to determine whether there are mutations or not.
- Call Details: Additional information for user to check assays in detail and perform additional analysis if necessary (one report for each chip).
Application note abstract:
Sequenom's MassARRAY® System* enables sensitive and rapid somatic mutation profiling in non-small cell lung carcinoma (NSCLC) samples. A new research use only LungCarta Panel offers highly valuable content with 214 mutations in 26 tumor suppressors and oncogenes.
We evaluated the LungCarta Panel against known standards, NCI-60 cell line DNA, and formalin-fixed paraffin embedded lung adenocarcinoma samples, and demonstrate that the panel provides a robust method for confirmation of known mutations.
Download the application note
|
|
|
For more information, please contact us or visit agenabioscience.com
|
|
|
|
